Efficacy of Adjunctive Alpha TRANSCRANIAL ALTERNATING CURRENT STIMULATION in Obsessive Compulsive Disorder.

Efficacy of adjunctive alpha TRANSCRANIAL ALTERNATING CURRENT STIMULATION in Obsessive Compulsive Disorder as measured by functional MAGNETIC RESONANCE IMAGING:A sham controlled study. - NIL

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/03/063896

Enrollment

Registered

2024-03-08

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F42- Obsessive-compulsive disorder

Interventions

Intervention1: Transcranial Alternating Current Stimulation(tACS) Active: Electrode positioning will be adjusted according to the 10–20 EEG system. The anode will be placed at Fp1 and the return elec

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosis of obsessive compulsive disorder according to ICD 11 DCR(WHO,2022). Age between 18- 60 years of either sex. Patients with YBOCS score of 16 or above. Patients should be on stable dose of antiobsessive and antipsychotic medications. Right-handed. Patients who have not received Cognitive Behavioural Therapy in the past 2 weeks of the study. Patients with mild to moderate depression associated with obsessive compulsive disorder. Patients giving written informed consent.

Exclusion criteria

Exclusion criteria: OCD with severe depression as measured by HDRS score more than 24. Presence of co-morbid neurological or other psychiatric disorder(s). Patient with co morbid substance dependence, except nicotine and caffeine. Having any metallic implants/parts in body. Patients not giving written informed consent

Design outcomes

Primary

Measure	Time frame
Reduction in YBOCS SCORE from baseline after application of 20 sessions of alpha tACS.Timepoint: Primary outcome variable will be Reduction in YBOCS SCORE from baseline at the end of 2 weeks after application of 20 sessions of alpha tACS.	—

Secondary

Measure	Time frame
Changes in BOLD activation in Orbitofrontal Cortex after application of 20 sessions of alpha tACS.Timepoint: Secondary outcome variable will be changes in BOLD activation in Orbitofrontal Cortex after application of 20 sessions of alpha tACS at the end of 2 weeks.	—

Countries

India

Contacts

Public ContactDr Daya Ram

Central Institute of Psychiatry

dram_cip@rediffmail.com7856866667

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026